MDT
Medtronic plc
Healthcare · Medical Devices · Ireland · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The composite score of 58.2 is anchored by a strong momentum sub-score of 16.0/20, reflecting genuine quarterly operational improvement captured in the FY2026 10-K, which prevented the score from falling into a lower tier.
- The financial health sub-score of 14.0/20 contributes meaningfully to the overall score, as the model rewards Medtronic's leverage discipline and interest coverage capacity as evidenced in the balance sheet and income statement filings.
- The dividend sub-score of 10.0/20 aligns with the company's 'Dividend Income' goal profile designation, contributing enough scoring weight to position Medtronic as a relevant research candidate for income-focused analysis even if not a top-tier dividend grower by the model's metrics.
Why Not Higher
- The growth sub-score of 10.0/20 and profitability sub-score of 13.2/20 are both below the upper half of their respective ranges, meaning the filing data did not demonstrate the combination of revenue acceleration and margin strength required to push the composite score above the mid-60s.
- The theme sub-score of 0.0/20 is a structural ceiling on the model score; with zero macro theme alignment captured from the filings, Medtronic forfeits up to 20 potential points that higher-scoring companies in growth-adjacent sectors tend to capture.
Data Confidence
10 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Medtronic plc is a global medical device company headquartered in Ireland that develops and manufactures therapies and diagnostics across cardiac rhythm management, surgical robotics, neuromodulation, diabetes management, and spine care, serving hospitals and patients in over 150 countries. The model assigned Medtronic a score of 58.2/100 based on FY2026 SEC EDGAR 10-K filings, reflecting a company with genuinely strong financial health (14.0/20) and solid fundamental momentum (16.0/20 — the highest sub-score, reflecting quarterly improvements in revenue, earnings, and margins), but constrained by modest growth metrics (10.0/20), middling profitability scores (13.2/20), and a theme score of zero, indicating no measurable exposure to the macro-level investment themes tracked by the model. The dividend sub-score of 10.0/20 is adequate but not exceptional, suggesting the FCF payout dynamics, dividend growth trajectory, or coverage ratios are neither a standout strength nor a material weakness. The central research tradeoff for Medtronic is between its operational stability and scale — evidenced by a strong balance sheet and improving quarterly fundamentals — and the drag from limited top-line growth momentum and thin margin expansion relative to what a higher score would require. The model labels this company 'Research Further' with a 'Dividend Income' goal profile, meaning the filing-derived data positions it most naturally as a candidate for researchers focused on steady income rather than high-growth compounding. The confidence of 10.0/10 on a full 10/10 metric mapping means the score is based on complete data with no imputation gaps.
Plain English
Medtronic is one of the world's largest medical device makers, producing everything from pacemakers to surgical robots to insulin pumps. A score of 58.2 out of 100 means the model sees this as a solid but not exceptional company — strong enough to merit further research, particularly if you are interested in dividend income, but not scoring high enough to stand out as a growth leader. The Low risk rating reflects a stable balance sheet and consistent financial profile as seen in its regulatory filings. Essentially, the model is saying Medtronic is a steady, mature business worth a closer look rather than a high-conviction standout.
Bull Case vs. Bear Case
Bull Case
- The momentum sub-score of 16.0/20 — the company's highest individual score — signals that quarterly revenue, earnings, and margin trends were improving across successive periods in the FY2026 10-K filing, suggesting the business is regaining operational traction.
- The financial health sub-score of 14.0/20 reflects a balance sheet characterized by manageable leverage, sufficient interest coverage, and meaningful balance sheet scale, which supports Medtronic's ability to sustain dividend payments and fund R&D through economic cycles.
- As the model's best-fit profile is dividend income, Medtronic's dividend sub-score of 10.0/20 combined with FCF coverage appears sufficient to support continued distributions, making it a research candidate for income-oriented strategies seeking lower-volatility healthcare exposure.
Bear Case
- The growth sub-score of 10.0/20 indicates that year-over-year revenue, net income, and EPS growth rates, as derived from the 10-K filing, are below the levels needed to drive a materially higher composite model score, suggesting limited organic expansion momentum.
- The profitability sub-score of 13.2/20 reflects net margins, operating margins, and return on assets that are adequate but not best-in-class for the medical device sector, limiting the model's confidence in Medtronic's earnings power relative to peers.
- The theme sub-score of 0.0/20 means the model found no measurable alignment with the macro-level investment themes it tracks, which reduces Medtronic's appeal to researchers seeking companies at the intersection of structural growth trends and current regulatory filings.
What Could Change the Picture
Bullish Triggers
- A future 10-K filing showing meaningfully accelerated year-over-year revenue growth and EPS expansion — particularly from its surgical robotics or diabetes care segments — would raise the growth sub-score and likely push the composite score above 65.
- Demonstrated improvement in net and operating margins leading to a higher profitability sub-score, potentially driven by post-restructuring efficiency gains or favorable product mix shift toward higher-margin therapies, would strengthen the overall research case.
Bearish Triggers
- A future filing revealing deteriorating interest coverage ratios, rising leverage, or declining free cash flow that undermines dividend coverage would weaken the financial health and dividend sub-scores that currently anchor the bull case for this company.
- If quarterly revenue and earnings trends reversed — reducing the momentum sub-score from its current 16.0/20 — the composite score could decline to a level where the 'Research Further' label is no longer supported by the model's data framework.
Red Flags
- The zero theme score, combined with a below-midpoint growth sub-score of 10.0/20, raises a question about whether Medtronic's top-line growth trajectory is sufficient to offset the natural margin pressure that large, mature medical device companies face from pricing and reimbursement dynamics.
Risk Profile
Low RiskThe Low risk rating for Medtronic reflects the filing-derived evidence of a large, well-capitalized balance sheet with manageable leverage and sufficient interest coverage, characteristics typical of a mature, diversified medical device company with multi-decade operating history. This rating does not imply absence of business or regulatory risk, but rather that the financial structure as reported in the FY2026 10-K does not exhibit the elevated leverage or earnings instability associated with higher-risk model profiles.
Key Catalysts to Watch
The key factor to watch in future filings is whether Medtronic can translate its current quarterly momentum — as evidenced by the 16.0/20 momentum sub-score — into sustained year-over-year growth that lifts the growth sub-score above its current 10.0/20 floor. Progress in higher-growth segments such as surgical robotics or diabetes technology, reflected in future 10-K revenue and margin disclosures, would be the most significant filing-derived signal for a re-rating of the composite model score.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.